Organosilicon molecules bind to the intrinsically disordered protein NUPR1 by clamping its hot-spots.

The nuclear protein 1, or NUPR1, is an intrinsically disordered protein (IDP) involved in the development and progression of pancreatic ductal adenocarcinoma (PDAC). We have previously developed drugs capable of binding at the two hot-spot regions of NUPR1, around residues Ala33 and Thr68, hampering its interactions in cellulo. In this work, we synthesized new organosilicon molecules targeting those key hot-spots. The compounds were obtained by an acid-catalyzed intramolecular cyclization of a starting alkenol that contains a silyl group attached to the double bond. Binding between the silyl compounds and NUPR1 involved the two hot-spots, as shown by 2D H-N HSQC NMR. Molecular simulations clarified that the binding relies on a loose clamp mechanism of the ligands towards the hot-spots. The dissociation constants (K) were around 20 μM, as measured by several biophysical techniques. However, studies in cellulo with PDAC cells did not show a decrease of cell viability upon treatment with the compounds; furthermore, proximity ligation assays in cellulo with a natural partner protein of NUPR1, G3BP, did not show a significant level of interfering in such interaction when silyl compounds were present, probably due to the high hydrophobicity of the designed compounds. Thus, in the case of NUPR1, moderate-to-high drug binding affinities (K < 10 μM) in vitro and a higher hydrophilicity are necessary to hamper protein-protein interactions in cellulo. As a more general conclusion, in vitro binding of ligands to the protein hot-spots is a necessary condition in the drug design targeting IDPs, but it is not enough to guarantee inhibition of their interactions in cellulo.